Ionis Pharmaceuticals
IONS
316 hedge funds and large institutions have $5.72B invested in Ionis Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 89 increasing their positions, 115 reducing their positions, and 38 closing their positions.
45% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 38
5% more funds holding
Funds holding: 301 → 316 (+15)
2% less capital invested
Capital invested by funds: $5.84B → $5.72B (-$114M)
1.41% less ownership
Funds ownership: 92.58% → 91.17% (-1.4%)
17% less call options, than puts
Call options by funds: $60.9M | Put options by funds: $73.5M
23% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 115
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$24.7M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$15M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.5M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$13.4M |
| 5 |
Goldman Sachs
New York
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$64.1M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$31.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$28.5M |
| 4 |
ClearBridge Investments
New York
|
-$25M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$19.5M |
IONS Hedge Fund Activity: Q4 2017 in Review
316 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2017, worth a combined $5.72B — down 2% from $5.84B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new IONS positions and 38 closed out — a net gain of 17 holders — while 89 added to existing stakes and 115 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $24.7M. The largest seller was Deutsche Bank, cutting an estimated $64.1M.
- 316 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2017, up from 301 in Q3 2017.
- Funds reported $5.72B of Ionis Pharmaceuticals stock for Q4 2017, down 2% quarter-over-quarter.
- 55 funds opened new Ionis Pharmaceuticals positions in Q4 2017 and 38 closed out, a net change of +17 holders.
- The largest Ionis Pharmaceuticals buyer in Q4 2017 was Boxer Capital, an estimated $24.7M added.
- The largest Ionis Pharmaceuticals seller in Q4 2017 was Deutsche Bank, an estimated $64.1M sold.
Based on aggregated 13F filings for Q4 2017.